

Bacteremia Caused by *Alistipes*

1 Title: **Retrospective Study of Bacteremia Caused by *Alistipes* Species in Japan, 2016–2023**

2

3 **Authors (ORCID):**

4 Naoki Watanabe (0000-0001-8609-4981), Tomohisa Watari (0000-0001-5507-8356), Naoto

5 Hosokawa (0009-0005-2858-1593), and Yoshihito Otsuka (No ID)

6

7 **Affiliation**

8 Kameda Medical Center, Kamogawa, Chiba, Japan (N. Watanabe, T. Watari, N. Hosokawa, Y.

9 Otsuka)

10 **Corresponding Author:** Naoki Watanabe

11 Kameda Medical Center, 296-0044, Higashi-cho 929, Kamogawa, Chiba, Japan

12 Phone: 81-04-7099-2323

13 Fax: 81-04-7099-1196

14 Email: watanabe.naoki.4@kameda.jp

15

16 **Word counts:**

17 Manuscript: 3163 words

18 Abstract: 150 words

19

20 **Keywords:** *Alistipes*, anaerobe, antimicrobial susceptibility, bacteremia, blood culture, infection

Bacteremia Caused by *Alistipes*

21 **Abstract**

22 The clinical characteristics of *Alistipes* bacteremia remain insufficiently described. Therefore,
23 here, we retrospectively analyzed 13 cases of *Alistipes* bacteremia at a tertiary care center to
24 evaluate their clinical and microbiological characteristics. Ten patients were aged ≥ 65 years, and
25 seven were female. Nine patients had comorbidities, including seven with solid tumors or
26 hematological malignancies. Eleven patients presented with gastrointestinal symptoms. The
27 isolates included four *Alistipes finegoldii*, four *Alistipes onderdonkii*, three *Alistipes putredinis*,
28 two *Alistipes indistinctus*, and one *Alistipes ihumii* isolates. Ten available strains exhibited low
29 minimum inhibitory concentrations against β -lactam/ β -lactamase inhibitors and metronidazole,
30 whereas they exhibited high minimum inhibitory concentrations for penicillin, ceftriaxone, and
31 minocycline. Several strains harbored antimicrobial resistance genes, including *adeF*, *tet(Q)*,
32 *cfxA3*, *cfxA4*, and *erm(G)*. Twelve patients received β -lactam/ β -lactamase inhibitors, and two
33 elderly patients with solid tumors developed septic shock and died. *Alistipes* species can
34 translocate from the gastrointestinal tract into the bloodstream, leading to severe infections.

35

Bacteremia Caused by *Alistipes*

36 **Introduction**

37 *Alistipes* is a rarely detected anaerobic bacterium in clinical samples. Initially described as a
38 bile-resistant, pigment-producing, Gram-negative bacillus (1, 2), *Alistipes* was classified as a new
39 genus in 2003 (3). The genus *Alistipes* includes 11 species, including *Alistipes finegoldii* (3),
40 *Alistipes putredinis* (3), and *Alistipes onderdonkii* (4). These species have been isolated from the
41 appendix tissue, feces, intra-abdominal fluid, and blood (3,5–7). Although the role of *Alistipes* in
42 humans remains unclear, this bacterium may play a preventive or pathogenic role in various
43 diseases. *Alistipes* may help to prevent colitis or contribute to the pathogenesis of depression
44 (8, 9).

45 Anaerobic bacteria, which are a part of the normal human flora, are also significant
46 pathogens in bacteremia and other infectious diseases. Anaerobic bacteremia is often associated
47 with abdominal, pelvic, skin, and soft tissue infections (10). *Alistipes* is associated with infections,
48 such as appendicitis (1, 2), and intra-abdominal infections (11). Three cases of *Alistipes*
49 bacteremia, with patients experiencing colon cancer (12) or peritonitis (13), have been reported.
50 Owing to the limited number of reports, the clinical characteristics of *Alistipes* bacteremia remain
51 insufficiently described.

Bacteremia Caused by *Alistipes*

52 Inadequate treatment of anaerobic bacterial infections can lead to clinical failure. In
53 cases of anaerobic bacteremia, the mortality rate is higher in patients receiving ineffective
54 antimicrobial therapy than in those receiving appropriate antimicrobial therapy (14). Therefore,
55 understanding the antimicrobial susceptibility of *Alistipes* species is crucial for implementing
56 effective treatments. Of the three *Alistipes* strains isolated from the blood, two of them have
57 shown low susceptibility to penicillin (PEN) and one to cefotetan (12, 13). Currently, the
58 antimicrobial susceptibility of *Alistipes* isolates from the blood is not well understood.

59 Therefore, this study aimed to investigate and describe the clinical characteristics of
60 *Alistipes* bacteremia in a tertiary care center in Japan. In addition, we evaluated the accuracy of
61 identification testing for *Alistipes* species and assessed the antimicrobial resistance of the isolates.

62 **Materials and Methods**

63 *Study Design and Data Collection*

64 This was a retrospective cohort study of *Alistipes* bacteremia at Kameda Medical Center in Japan
65 conducted between April 2016 and December 2023. We reviewed 31,875 patients who underwent
66 blood cultures and identified *Alistipes* cases. For patients with multiple episodes, only the first

Bacteremia Caused by *Alistipes*

67 episode was included in this study. Patient data and microbiological testing results were collected
68 from medical records and a laboratory system. Patient data included age, sex (male or female),
69 infection type (community-acquired, healthcare-associated), comorbidities, symptoms, infection
70 sites, procedures, antimicrobial therapy, hospitalization days from blood collection, and outcomes.
71 Healthcare-associated infections were defined as cases with one of the following conditions:
72 onset after 48 h of hospitalization or patients receiving medical care, such as a nursing home,
73 dialysis, or outpatient chemotherapy. The Ethics Committee of Kameda Medical Center approved
74 this study (agreement no. 23-121). Written informed consent was not required because the data
75 used were anonymized.

76 ***Blood Culture and Identification Testing***

77 Blood cultures were performed using BD Bactec™ FX Blood Culture System (Becton, Dickinson
78 and Company, <https://www.bd.com>). Blood samples were collected using Plus Aerobic and Lytic
79 Anaerobic Media for adult patients and Peds Plus Medium for pediatric patients (Becton,
80 Dickinson and Company). The blood cultures were incubated at 35 °C for 7 days. The number of
81 positive blood culture sets, time to positivity, and detected *Alistipes* were recorded. *Alistipes*
82 strains were stored at –80 °C for identification, whole genome sequencing, and antimicrobial
83 susceptibility testing. The preserved strains were cultured anaerobically using Brucella HK agar

Bacteremia Caused by *Alistipes*

84 medium (Kyokuto Pharmaceutical Industrial, <https://www.kyokutoseiyaku.co.jp>) at 35 °C for 2
85 days and were used for each test.

86 The strains were identified using matrix-assisted laser desorption/ionization
87 time-of-flight mass spectrometry (MALDI-TOF MS). MALDI-TOF MS was performed using the
88 MALDI Biotyper system, which included the microflex LT/SH and flexControl version 3.4
89 (Bruker Daltonics GmbH, <https://www.bruker.com>). *Alistipes* colonies that developed on the
90 Brucella HK agar medium were selected and applied to the test plate. Mass spectra were analyzed
91 using the MALDI Biotyper Library, which recorded the highest score for the predicted species.
92 Identification results were accepted at the species level for scores of ≥ 2.0 . In cases where an
93 identification result could not be obtained using the standard cell smear method, the strains were
94 retested using the formic acid on-plate or formic acid extraction method.

95 ***Polymerase Chain Reaction (PCR) and Whole Genome Analysis***

96 The identification results were validated by 16S rRNA gene and whole genome analyses of the
97 preserved strains. Non-preserved strains were excluded from this analysis. Genomic DNA was
98 extracted from the strains using magLEAD and Consumable Kits (Precision System Science;
99 <https://www.pss.co.jp>). GeneAtlas Type G (Astec, <https://www.astec-corp.co.jp>) was used as the

Bacteremia Caused by *Alistipes*

100 thermal cycler and Premix Taq Hot Start Version (Takara Bio, <https://www.takara-bio.com>) for
101 the PCR reagent. Using previously reported primers for the 16S rRNA gene (15, 16), PCR was
102 performed according to the literature (17). PCR conditions and primers used are listed in Table
103 S1. Sequencing was performed using FASMAC (<https://fasmac.co.jp>), and the resulting
104 sequences were analyzed using EzBioCloud (18) for species identification. Additionally, 16S
105 rRNA gene reanalysis was performed on three *A. finegoldii* strains (3302398, 4401054, and
106 Granada) from previous bacteremia cases (12, 13). The sequence data for 3302398 (accession no.
107 AY547271), 4401054 (AY643082), and Granada (OM900033) were obtained from GenBank and
108 analyzed using the same methods as the strains collected in this study.

109 Fragment libraries for the whole genome analysis were prepared using Illumina DNA
110 Prep Tagmentation (M) Beads (Illumina, <https://www.illumina.com>). Sequencing was performed
111 using the MiSeq Reagent Micro Kit (Illumina) to generate paired-end reads. De novo assembly
112 was conducted using the CLC Genomics Workbench version 22.0.2 (Qiagen,
113 <https://www.qiagen.com>). CheckM (19) was used as a quality check for the genome, and samples
114 with a contamination rate of $\geq 5\%$ were excluded from subsequent analysis. The average
115 nucleotide identity (ANI) was performed using DFAST (20), identifying bacterial species with a
116 threshold of $\geq 95\%$. For subspecies analysis, DNA-DNA hybridization (DDH) analysis was

Bacteremia Caused by *Alistipes*

117 performed using the Genome–Genome Distance Calculator 3.0 (<https://ggdc.dsmz.de>) (21). The
118 threshold for defining subspecies was set at 79% DDH of the previously reported criteria for
119 subspecies classification (22). The presence of antimicrobial resistance genes was analyzed using
120 the Comprehensive Antibiotic Resistance Database (23).

121 *Antimicrobial Susceptibility Testing*

122 The antimicrobial susceptibility of the preserved strains was evaluated using the broth
123 microdilution method with Brucella Broth and Dry Plates (Eiken Chemical,
124 <https://www.eiken.co.jp>). The inoculum was prepared according to the manufacturer's
125 instructions and transferred to a microplate at a final volume of approximately 1×10^5
126 colony-forming unit per well. After inoculation, the microplate was incubated anaerobically at
127 35–37 °C for 46–48 h. Minimum inhibitory concentrations (MICs) were determined after
128 confirming bacterial growth in the control wells. The Dry Plate included the following
129 antibiotics: PEN, ampicillin-sulbactam (SAM), amoxicillin-clavulanic acid (AMC),
130 piperacillin-tazobactam (TZP), ceftriaxone (CRO), cefoxitin (FOX), imipenem (IPM),
131 clindamycin (CLI), minocycline (MINO), moxifloxacin (MXF), and metronidazole (MTZ). After
132 determining the MICs, the concentrations required to inhibit 50% and 90% of the strains (MIC₅₀
133 and MIC₉₀) were calculated.

Bacteremia Caused by *Alistipes*

134 *Statistical Analyses*

135 The characteristics of *Alistipes* cases were summarized using EZR version 1.54 (24). Continuous
136 variables are reported as medians and interquartile ranges (IQRs), and categorical variables are
137 reported as actual numbers. The proportion of patients with *Alistipes* bacteremia among all
138 patients who underwent blood culture was calculated using 95% confidence intervals. Time to
139 positivity was reported as the median and IQR, excluding the results from blood culture sets with
140 multiple pathogens.

141 **Results**

142 *Patient Characteristics and Clinical Courses*

143 Thirteen *Alistipes* bacteremia were identified over a 7-year period. This number represented
144 0.04% of the patients with blood cultures, and all cases were single episodes. The characteristics
145 of the patients with *Alistipes* bacteremia are shown in Table 1. The median patient age was 72
146 (IQR, 65–85) years, and 10 patients were aged > 65 years. Seven patients were female, and nine
147 patients had comorbid conditions, with a Charlson score ≥ 1 . Six patients had solid tumors, and
148 one had a hematological malignancy. The most common clinical symptom was abdominal pain
149 (nine patients), followed by fever (six patients). Of the 13 patients, 11 presented with

Bacteremia Caused by *Alistipes*

150 gastrointestinal symptoms, including abdominal pain, vomiting, diarrhea, and/or abdominal
151 distention. The median time to positivity was 81 (IQR, 71–106) h, and *Alistipes* strains from three
152 cases were detected in blood cultures that tested positive \geq 120 h after the start of incubation.
153 Four patients had two sets of positive blood cultures.

154 The clinical presentations, treatments, and outcomes of *Alistipes* bacteremia are
155 summarized in Table 2. Eleven of thirteen patients were diagnosed with gastrointestinal tract
156 disease, with infection sites in these areas. The remaining two patients had *Alistipes* bacteremia
157 with unknown infection sites (cases 7 and 12). The patient in case 7 developed a fever during
158 treatment for a catheter-related bloodstream infection caused by *Staphylococcus aureus*, and
159 *Alistipes indistinctus* was detected in a blood culture collected at the time of fever. The patient in
160 case 12 had a history of a cerebral infarction and cholecystectomy. The patient presented with
161 chills, fever, and vomiting, and blood cultures were positive for *A. putredinis*. All patients were
162 clinically diagnosed with true bacteremia and received antimicrobial therapy. The duration of the
163 antimicrobial therapy ranged from 13 to 36 days. The most commonly prescribed antimicrobials
164 were β -lactam/ β -lactamase inhibitors (BLBLIs), with nine patients receiving SAM and six
165 patients receiving TZP. Six patients were positive for multiple pathogens, including *Escherichia*
166 *coli*, *Klebsiella pneumoniae*, *Bacteroides* species, and others.

Bacteremia Caused by *Alistipes*

167 *Clinical Outcomes*

168 Of the 13 patients, 11 achieved clinical resolution following antimicrobial therapy, whereas the
169 remaining 2 (cases 1 and 8) had a fatal outcome. The patient in fatal case 1 was a woman in her
170 80s with rectal cancer and liver metastases, who was admitted to the hospital for abdominal pain.
171 Upon arrival at the hospital, the patient experienced septic shock. The patient received
172 intravenous fluids, blood cultures were obtained, and TAZ and VCM were administered. Her
173 condition briefly stabilized following the infusion, but subsequently deteriorated with the
174 development of acidosis, hyperkalemia, and elevated lactic acid levels. The patient was
175 diagnosed with colonic perforation and obstruction. The decision was made to transfer the patient
176 to a hospital near her home for palliative care and to discontinue aggressive treatment. However,
177 her condition deteriorated, and she died within the day of the transfer. After the patient died, *A.*
178 *fingoldii* was detected in the blood culture obtained during an episode of septic shock.

179 The patient in fatal case 8 was a man in his 70s who was hospitalized for a
180 comprehensive evaluation of adenocarcinoma of unknown primary origin. The patient was
181 administered fluconazole for oral candidiasis. During hospitalization, the patient developed septic
182 shock and was administered intravenous fluids. Blood cultures were obtained, and TAZ was
183 administered. Although the patient initially stabilized, he later developed fecal emesis, likely due

Bacteremia Caused by *Alistipes*

184 to intestinal obstruction. One day after the onset, the patient eventually died of septic shock.

185 Blood cultures obtained during a septic shock episode revealed the presence of *A. onderdonkii*.

186 ***Microbiological Characteristics***

187 The microbiological characteristics of the *Alistipes* cases and strains are presented in Table 3.

188 *Alistipes* strains formed small colonies on the Brucella HK agar medium (Fig. 1). MALDI-TOF

189 MS identified 13 strains with species-level accuracy, including *A. finegoldii* (n = 4), *A.*

190 *onderdonkii* (n = 4), *A. putredinis* (n = 3), and *A. indistinctus* (n = 2). Of the 13 strains, 16S

191 rRNA and whole genome analyses were performed on 10 preserved strains (KML 24001–24010).

192 16S rRNA gene analysis showed that 10 of the preserved strains were 99.8–100% similar to the

193 species identified by MALDI-TOF MS (Table S2).

194 The draft genomes of nine strains (KML 24001-24009) had contamination rates of < 1%

195 and were used for further analysis (Table S3). One remaining strain (KML 24010) had a

196 contamination rate of > 5% and was excluded from further analysis. The genome sizes of *A.*

197 *finegoldii*, *A. onderdonkii*, *A. putredinis*, and *A. indistinctus* were 3.6 Mb, 3.3–3.6 Mb, 2.5–2.8

198 Mb, and 2.8–2.9 Mb, respectively (Table S4). The ANI results of KML 24001-24009 were in

199 agreement with the results of MALDI-TOF MS, with an ANI of 99.8–100% (Table S5). DDH

Bacteremia Caused by *Alistipes*

200 analysis for *A. onderdonkii* revealed that KML 24001 and KML 24005 showed DDH > 80% only
201 for *A. onderdonkii* subsp. *vulgaris*, and KML 24008 showed DDH > 80% only for *A. onderdonkii*
202 subsp. *onderdonkii*. The subspecies of each strain were identified (Table S6).

203 Strains with > 5% contamination were pure-cultured, and the two types of colonies
204 grown were re-identified by MALDI-TOF MS. One strain (KML 24010) was identified as
205 *A. finegoldii* by MALDI-TOF MS, and this strain showed 99.8% similarity to *A. finegoldii* by
206 16S rRNA gene analysis. Another strain (KML 24011) was not identified by MALDI-TOF MS
207 and showed 99.7% similarity to *A. ihumii* AP11 (JX101692). The 16S rRNA gene sequence and
208 draft genome data were deposited in GenBank via the DNA DataBank of Japan, and the
209 accession numbers are given in Tables S2 and S4.

210 Reanalysis of the three *A. finegoldii* strains (3302398, 4401054, and Granada) isolated in
211 previous reports yielded the following results: strain 3302398 showed 100% similarity to
212 *A. dispar* 5CPEGH6 (accession no. AP019736), and strain 4401054 showed 99.0–100%
213 similarity to *A. onderdonkii* subsp. *onderdonkii* DSM 19147 (ARFY01000017). Strain Granada
214 showed 97.6% similarity with *A. finegoldii* DSM 17242 (CP003274); however, the species could
215 not be confirmed.

Bacteremia Caused by *Alistipes*

216 ***Antimicrobial Susceptibility and Resistance Genes***

217 Antimicrobial susceptibility data were available for *Alistipes* 10 strains (Table 4). Low MIC₉₀
218 values were observed for SAM (MIC₉₀, 2 µg/mL), AMC (2 µg/mL), TZP (≤ 4 µg/mL), IPM
219 (1 µg/mL), CLI (1 µg/mL), and MTZ (0.5 µg/mL). For CLI, only one *A. putredinis* strain showed
220 an MIC of 2 µg/mL, and this strain possessed the *erm*(G) gene. The antibiotics with high MIC₉₀
221 values were PEN (MIC₉₀, > 1 µg/mL), CRO (> 32 µg/mL), FOX (32 µg/mL), MINO (8 µg/mL),
222 and MXF (> 4 µg/mL). MICs were particularly high for PEN and MINO, with MIC₅₀ values of
223 > 1 µg/mL and 4 µg/mL, respectively. Seven strains with MICs ≥ 4 µg/mL for MINO harbored
224 the *adeF* and *tet*(Q) genes. Two strains exhibited MICs of 32 µg/mL for FOX, and these strains
225 were all *A. indistinctus*. Three strains showed MICs ≥ 4 µg/mL for MXF, all of which were
226 *A. onderdonkii*.

227 **Discussion**

228 In this study, we identified 13 cases of *Alistipes* bacteremia at a single institution in Japan. Three
229 main characteristics were observed in patients with *Alistipes* bacteremia. First, most patients were
230 elderly or had comorbid conditions, with 7 of the 13 patients having either solid tumors or
231 hematological malignancies. Second, general cases were associated with gastrointestinal diseases,

Bacteremia Caused by *Alistipes*

232 and all patients were treated for true bacteremia. Third, some *Alistipes* strains had high MICs
233 against β -lactams, tetracyclines, and quinolones, indicating the presence of antibiotic-resistant
234 genes.

235 Anaerobic bacteria can cause infections in almost any part of the body, including severe
236 bloodstream infections (25). In our study, 13 cases of bacteremia were caused by *A. finegoldii*,
237 *A. putredinis*, *A. onderdonkii* subsp. *onderdonkii*, *A. onderdonkii* subsp. *vulgaris*, *A. indistinctus*,
238 and *A. ihumii*. There have only been three *A. finegoldii* cases of *Alistipes* bacteremia reported to
239 date (12, 13), and Tyrrel et al. reported one of these strains (strain 4401054) to be *A. onderdonkii*
240 (7). Our data support the report by Tyrrel et al., who showed that another strain (strain 3302398)
241 was *A. dispar*. Slow growth and difficulty in identification probably contribute to the
242 underestimation of *Alistipes* bacteremia. Compared with other bacteria, such as *E. coli* and
243 *Bacteroides* species, *Alistipes* grows more slowly and forms significantly small colonies.
244 Additionally, *Alistipes* is difficult to identify to by biochemical characteristics. However, the
245 advent of MALDI-TOF MS has improved the ability to accurately identify anaerobes, including
246 lesser known pathogens (25, 26). Our study showed that MALDI-TOF MS could identify *Alistipes*
247 strains with high accuracy, in agreement with 16S rRNA gene analysis and whole genome
248 sequencing. Although *Alistipes* bacteremia has not been recognized until recently, the number of

Bacteremia Caused by *Alistipes*

249 cases is expected to increase in the future.

250 *Alistipes* species have been isolated from feces (3, 6, 27), and *A. putredinis* is commonly
251 found in the gut microbiota (28). In previous cases of *Alistipes* bacteremia, two patients had colon
252 cancer (12), and the other had intestinal perforation and peritonitis (13). Similarly, in our study,
253 most patients (11/13) had underlying gastrointestinal symptoms. These findings suggest that
254 *Alistipes* translocates from the gastrointestinal tract into the bloodstream. In our cohort, all
255 patients were treated with antibiotics for true bacteremia, and 11 recovered. Two patients who
256 died were aged ≥ 70 years, had solid tumors, and developed sepsis. These patients had
257 monomicrobial bacteremia caused by *Alistipes* and were treated with antibiotics to which the
258 isolates were susceptible. The fatal outcomes were likely due to the complications of sepsis and
259 the effects of underlying malignancies.

260 *Alistipes* strains showed different antimicrobial susceptibilities depending on the species
261 and strain. All the strains showed low MIC values for BLBLIs, IPM, and MNZ. Consistent with
262 our findings, previously reported strains were also susceptible to SAM (7), TZP (13), and MNZ
263 (3, 7, 13). In our cohort, 12 patients were treated with BLBLIs and 10 recovered. In previously
264 reported cases of *Alistipes* bacteremia, three patients were successfully treated with combinations
265 of AMC and ciprofloxacin, AMC and amikacin, or TZP and MTZ (12, 13). BLBLIs and MNZ

Bacteremia Caused by *Alistipes*

266 are commonly used for anaerobic infections (29) and can be an option for the treatment of
267 *Alistipes* bacteremia.

268 Conversely, several *Alistipes* strains were resistant to PEN, CRO, MINO, MXF, and
269 FOX. Low susceptibility to MXF and FOX was observed only in *A. onderdonkii* and
270 *A. indistinctus*. Moreover, our data revealed the presence of antibiotic-resistant genes, such as
271 *adeF*, *tet(Q)*, *cfxA3*, *cfxA4*, and *erm(G)*. Consistent with our findings, previous reports have
272 indicated resistance to PEN (11–13), tetracyclines (3), and MXF (11) in *Alistipes* strains.
273 Although breakpoints for *Alistipes* have not been established by the Clinical and Laboratory
274 Standards Institute (30), it may be prudent to avoid using antibiotics that have been observed to
275 have low susceptibility for the treatment of *Alistipes* bacteremia.

276 The limitations of this study are its single-center design and the limited number of cases.
277 As this was a single-center study, the generalizability of patient and strain characteristics is
278 limited. The limited number of cases for each strain prevented statistical comparisons of patient
279 backgrounds and antimicrobial susceptibilities between the species. Therefore, future studies
280 should include a wider range of regions and institutions. Moreover, some strains were not
281 preserved, which limited the validation of the identification tests and antimicrobial susceptibility
282 measurements for these non-preserved strains. Furthermore, discrepancies between phenotypic

Bacteremia Caused by *Alistipes*

283 and genotypic antimicrobial susceptibilities were observed, and not all resistance mechanisms
284 could be elucidated. Our study highlights the need for further evaluation, including mutational
285 analysis and efflux pump assessment, to fully understand the resistance mechanisms.

286 In conclusion, 13 cases of *Alistipes* bacteremia were observed over a 7-year period at a
287 tertiary care center in Japan. Most patients were elderly and had comorbid conditions involving
288 solid tumors or hematological malignancies. The most common symptoms were gastrointestinal,
289 and two of the patients died of sepsis. MALDI-TOF MS will facilitate the identification of
290 *Alistipes* strains, and reports of *Alistipes* bacteremia are predicted to increase.

291 **About the Author**

292 Naoki Watanabe is a clinical laboratory scientist specializing in infectious disease at Kameda
293 Medical Center in Kamogawa, Japan. His primary interests include infectious diseases,
294 microbiological testing, and antimicrobial stewardship.

295 **Acknowledgment**

296 We thank the clinical laboratory scientist at Kameda Medical Center for their assistance with
297 microbiological testing.

Bacteremia Caused by *Alistipes*

298 **Conflict of interest**

299 The authors declare that there are no conflicts of interest.

300

Bacteremia Caused by *Alistipes*

301 REFERENCES

- 302 1. Rautio M, Lönnroth M, Saxén H, Nikku R, Väisänen ML, Finegold SM, et al. Characteristics
303 of an unusual anaerobic pigmented gram-negative rod isolated from normal and inflamed
304 appendices. *Clin Infect Dis*. 1997 Sep;25 Suppl 2:S107–10. <http://dx.doi.org/10.1086/516210>
- 305 2. Rautio M, Saxén H, Siitonen A, Nikku R, Jousimies-Somer H. Bacteriology of
306 histopathologically defined appendicitis in children. *Pediatr Infect Dis J*. 2000
307 Nov;19(11):1078–83. <http://dx.doi.org/10.1097/00006454-200011000-00010>
- 308 3. Rautio M, Eerola E, Väisänen-Tunkelrott ML, Molitoris D, Lawson P, Collins MD, et al.
309 Reclassification of *Bacteroides putredinis* (Weinberg et al., 1937) in a new genus *Alistipes*
310 gen. nov., as *Alistipes putredinis* comb. nov., and description of *A. finegoldii* sp. nov., from
311 human sources. *Syst Appl Microbiol*. 2003 Jun;26(2):182–8.
312 <http://dx.doi.org/10.1078/072320203322346029>
- 313 4. Song Y, Könönen E, Rautio M, Liu C, Bryk A, Eerola E, et al. *Alistipes onderdonkii* sp. nov.
314 and *Alistipes shahii* sp. nov., of human origin. *Int J Syst Evol Microbiol*. 2006 Aug;56(Pt
315 8):1985–90. <http://dx.doi.org/10.1099/ijs.0.64318-0>
- 316 5. Simmon KE, Mirrett S, Reller LB, Petti CA. Genotypic diversity of anaerobic isolates from
317 bloodstream infections. *J Clin Microbiol*. 2008 May;46(5):1596–601.
318 <http://dx.doi.org/10.1128/JCM.02469-07>
- 319 6. Nagai F, Morotomi M, Watanabe Y, Sakon H, Tanaka R. *A. indistinctus* sp. nov. and
320 *Odoribacter laneus* sp. nov., common members of the human intestinal microbiota isolated
321 from faeces. *Int J Syst Evol Microbiol*. 2010 Jun;60(Pt 6):1296–302.
322 <http://dx.doi.org/10.1099/ijs.0.014571-0>
- 323 7. Tyrrell KL, Warren YA, Citron DM, Goldstein EJC. Re-assessment of phenotypic

Bacteremia Caused by *Alistipes*

- 324 identifications of *Bacteroides putredinis* to *Alistipes* species using molecular methods.
325 Anaerobe. 2011 Jun;17(3):130–4. <http://dx.doi.org/10.1016/j.anaerobe.2011.04.002>
- 326 8. Dziarski R, Park SY, Kashyap DR, Dowd SE, Gupta D. Pglyrp-Regulated Gut Microflora
327 Prevotella falsenii, ParaBacteroides distasonis and Bacteroides eggerthii Enhance and A.
328 *fingoldii* Attenuates Colitis in Mice. PLoS One. 2016 Jan 4;11(1):e0146162.
329 <http://dx.doi.org/10.1371/journal.pone.0146162>
- 330 9. Naseribafrouei A, Hestad K, Avershina E, Sekelja M, Linløkken A, Wilson R, et al.
331 Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil.
332 2014 Aug;26(8):1155–62. <http://dx.doi.org/10.1111/nmo.12378>
- 333 10. Lassmann B, Gustafson DR, Wood CM, Rosenblatt JE. Reemergence of anaerobic
334 bacteremia. Clin Infect Dis. 2007 Apr 1;44(7):895–900. <http://dx.doi.org/10.1086/512197>
- 335 11. Cobo F, Foronda C, Pérez-Carrasco V, Martín-Hita L, García-Salcedo JA, Navarro-Marí JM.
336 First description of abdominal infection due to *Alistipes onderdonkii*. Anaerobe. 2020
337 Dec;66:102283. <http://dx.doi.org/10.1016/j.anaerobe.2020.102283>
- 338 12. Fenner L, Roux V, Ananian P, Raoult D. *A. fingoldii* in blood cultures from colon cancer
339 patients. Emerg Infect Dis. 2007 Aug;13(8):1260–2.
340 <http://dx.doi.org/10.3201/eid1308.060662>
- 341 13. Cobo F, Franco-Acosta A, Lara-Oya A, Pérez-Carrasco V. Bacteremia caused by *A.*
342 *fingoldii* in a patient with peritonitis. Enferm Infecc Microbiol Clin. 2023 Feb;41(2):131–2.
343 <http://dx.doi.org/10.1016/j.eimce.2022.11.002>
- 344 14. Salonen JH, Eerola E, Meurman O. Clinical significance and outcome of anaerobic
345 bacteremia. Clin Infect Dis. 1998 Jun;26(6):1413–7. <http://dx.doi.org/10.1086/516355>
- 346 15. Lane DJ. 16S/23S rRNA sequencing. Nucleic acid techniques in bacterial systematics. 1991;
347 <https://cir.nii.ac.jp/crid/1570009750603612672>

Bacteremia Caused by *Alistipes*

- 348 16. Jaric M, Segal J, Silva-Herzog E, Schneper L, Mathee K, Narasimhan G. Better primer
349 design for metagenomics applications by increasing taxonomic distinguishability. *BMC Proc.*
350 2013 Dec 20;7(Suppl 7):S4. <http://dx.doi.org/10.1186/1753-6561-7-S7-S4>
- 351 17. Watanabe N, Watari T, Otsuka Y, Hosokawa N, Yamagata K, Fujioka M. Clinical and
352 microbiological characteristics of *Ruminococcus gnavus* bacteremia and intra-abdominal
353 infection. *Anaerobe*. 2024 Jan 9;102818. <http://dx.doi.org/10.1016/j.anaerobe.2024.102818>
- 354 18. Yoon SH, Ha SM, Kwon S, Lim J, Kim Y, Seo H, et al. Introducing EzBioCloud: a
355 taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies.
356 *Int J Syst Evol Microbiol*. 2017 May;67(5):1613–7. <http://dx.doi.org/10.1099/ijsem.0.001755>
- 357 19. Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. CheckM: assessing the
358 quality of microbial genomes recovered from isolates, single cells, and metagenomes.
359 *Genome Res*. 2015 Jul;25(7):1043–55. <http://dx.doi.org/10.1101/gr.186072.114>
- 360 20. Tanizawa Y, Fujisawa T, Nakamura Y. DFAST: a flexible prokaryotic genome annotation
361 pipeline for faster genome publication. *Bioinformatics*. 2018 Mar 15;34(6):1037–9.
362 <http://dx.doi.org/10.1093/bioinformatics/btx713>
- 363 21. Meier-Kolthoff JP, Carbasse JS, Peinado-Olarte RL, Göker M. TYGS and LPSN: a database
364 tandem for fast and reliable genome-based classification and nomenclature of prokaryotes.
365 *Nucleic Acids Res*. 2022 Jan 7;50(D1):D801–7. <http://dx.doi.org/10.1093/nar/gkab902>
- 366 22. Meier-Kolthoff JP, Hahnke RL, Petersen J, Scheuner C, Michael V, Fiebig A, et al.
367 Complete genome sequence of DSM 30083(T), the type strain (U5/41(T)) of *Escherichia*
368 *coli*, and a proposal for delineating subspecies in microbial taxonomy. *Stand Genomic Sci.*
369 2014 Dec 8;9:2. <http://dx.doi.org/10.1186/1944-3277-9-2>
- 370 23. Alcock BP, Huynh W, Chalil R, Smith KW, Raphenya AR, Wlodarski MA, et al. CARD
371 2023: expanded curation, support for machine learning, and resistome prediction at the

Bacteremia Caused by *Alistipes*

- 372 Comprehensive Antibiotic Resistance Database. *Nucleic Acids Res.* 2023 Jan
373 6;51(D1):D690–9. <http://dx.doi.org/10.1093/nar/gkac920>
- 374 24. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical
375 statistics. *Bone Marrow Transplant.* 2013 Mar;48(3):452–8.
376 <http://dx.doi.org/10.1038/bmt.2012.244>
- 377 25. Nagy E, Boyanova L, Justesen US, ESCMID Study Group of Anaerobic Infections. How to
378 isolate, identify and determine antimicrobial susceptibility of anaerobic bacteria in routine
379 laboratories. *Clin Microbiol Infect.* 2018 Nov;24(11):1139–48.
380 <http://dx.doi.org/10.1016/j.cmi.2018.02.008>
- 381 26. Justesen Ulrik Stenz, Holm Anette, Knudsen Elisa, Andersen Line Bisgaard, Jensen Thøger
382 Gorm, Kemp Michael, et al. Species Identification of Clinical Isolates of Anaerobic Bacteria:
383 a Comparison of Two Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass
384 Spectrometry Systems. *J Clin Microbiol.* 2020 Dec 21;49(12):4314–8.
385 <https://doi.org/10.1128/jcm.05788-11>
- 386 27. Sakamoto M, Ikeyama N, Ogata Y, Suda W, Iino T, Hattori M, et al. *Alistipes communis* sp.
387 nov., *A. dispar* sp. nov. and *Alistipes onderdonkii* subsp. vulgaris subsp. nov., isolated from
388 human faeces, and creation of *Alistipes onderdonkii* subsp. *onderdonkii* subsp. nov. *Int J Syst*
389 *Evol Microbiol.* 2020 Jan;70(1):473–80. <http://dx.doi.org/10.1099/ijsem.0.003778>
- 390 28. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial
391 gene catalogue established by metagenomic sequencing. *Nature.* 2010 Mar
392 4;464(7285):59–65. <http://dx.doi.org/10.1038/nature08821>
- 393 29. Brook I, Wexler HM, Goldstein EJC. Antianaerobic antimicrobials: spectrum and
394 susceptibility testing. *Clin Microbiol Rev.* 2013 Jul;26(3):526–46.
395 <http://dx.doi.org/10.1128/CMR.00086-12>

Bacteremia Caused by *Alistipes*

- 396 30. Clinical and Laboratory Standards Institute - Performance Standards for Antimicrobial
397 Susceptibility Testing, 34th Edition. [cited 2024 July 1]. <https://em100.edaptivedocs.net>

398

Bacteremia Caused by *Alistipes*

399 **Table 1.** Patient background of *Alistipes* bacteremia in a tertiary care center in Japan, 2016–2023

Characteristics	All (n = 13)	Alive (n = 11)	Death (n = 2)
Age, median years (IQR)	72 (65–85)	70 (59–85)	80 (78–83)
≥ 65 years, no. (%)	10 (76.9)	8 (72.7)	2 (100.0)
Sex, F, no. (%)	7 (53.8)	6 (54.5)	1 (50.0)
Site of acquisition, no. (%)			
Community	7 (53.8)	7 (63.6)	0 (0.0)
Healthcare-associated	6 (46.2)	4 (36.4)	2 (100.0)
Charlson score, no. (%)			
0	4 (30.8)	4 (36.4)	0 (0.0)
1–2	4 (30.8)	3 (27.3)	1 (50.0)
3–4	2 (15.4)	2 (18.2)	0 (0.0)
≥ 5	3 (23.1)	2 (18.2)	1 (50.0)
Comorbid conditions, no. (%)			
Solid tumor	6 (46.2)	4 (36.4)	2 (100.0)
Hematological malignancies	1 (7.7)	1 (9.1)	0 (0.0)
Leukopenia	2 (15.4)	2 (18.2)	0 (0.0)
Chemotherapy	3 (23.1)	3 (27.3)	0 (0.0)
Immunosuppressive therapy	0 (0.0)	0 (0.0)	0 (0.0)
Intravascular device, no. (%)	3 (23.1)	2 (18.2)	1 (50.0)
Symptoms, no. (%)			
Abdominal pain	9 (69.2)	8 (72.7)	1 (50.0)
Diarrhea	1 (7.7)	1 (9.1)	0 (0.0)
Sepsis or septic shock	3 (23.1)	1 (9.1)	2 (100.0)
Fever	6 (46.2)	6 (54.5)	0 (0.0)
Vomiting	3 (23.1)	3 (27.3)	0 (0.0)
Time to positivity, h (IQR)	81 (71–106)	76 (68–103)	94 (88–99)

Bacteremia Caused by *Alistipes*

401 **Table 2.** Patient characteristics and clinical course of *Alistipes* bacteremia in a tertiary care center in Japan, 2016–2023

Case ID	Age/sex	Comorbid conditions	Clinical presentation	Clinical diagnosis	Therapy [†]	Outcome
1	80s/F	Hypertension, diabetes mellitus, lipid disorder, cerebral infarction history, rectal cancer	Abdominal pain, septic shock	Colon perforation, colonic obstruction	TZP and VCM (1 day)	Death (1 day)
2*	50s/M	None	Abdominal pain	Acute appendicitis	SAM (3 days), AMC (11 days), appendicectomy	Alive, discharged (6 days)
3	50s/F	Ovarian cancer, febrile neutropenia	Abdominal pain, fever	Perforated colon	SAM (24 days), TZP (12 days)	Alive, discharged (50 days)
4	90s/F	Alzheimer's type dementia, Hypertension, epilepsy, chronic constipation	Abdominal pain, vomiting, diarrhea, fever	Acute appendicitis, secondary peritonitis, paralytic ileus, aspiration pneumonia	SAM (23 days), AMC (5 days)	Alive, discharged (22 days)
5*	60s/F	Diabetes mellitus, colon cancer	Abdominal pain, septic shock	Generalized peritonitis, intestinal perforation, Nonocclusive mesenteric ischemia, ovarian necrosis	TZP (2 days), CMZ (17 days), colectomy, small bowel resection, bilateral salpingo-oophorectomy	Alive, transferred (114 days)
6	70s/M	Febrile neutropenia, previous hepatitis B virus infection, hypertension, diabetes mellitus, benign prostatic hyperplasia, acute myeloid leukemia	Fever, abdominal pain	Colonic diverticulitis	Cefepime and MTZ (10 days), SAM and MTZ (3 days)	Alive, discharged (228 days)
7	30s/M	Epilepsy, under treatment for CRBSI with <i>Staphylococcus aureus</i>	Fever	Bacteremia of unknown origin	Cefazolin (5 days), SAM (12 days)	Alive, transferred (41 days)
8	70s/M	Oral candida, adenocarcinoma (primary site unknown)	Septic shock, ascites, abdominal	Bowel obstruction	TZP (1 day), TZP and fluconazole (1 day)	Death (1 day)

Bacteremia Caused by *Alistipes*

			distension			
9*	60s/F	Rectal cancer	Abdominal pain, vomiting	Colon perforation, peritonitis	TZP (1 day), SAM (14 days), Hartmann's procedure	Alive, discharged (28 days)
10*	90s/F	Hypertension, dyslipidemia, osteoporosis, postoperative Mallory–Weiss syndrome, suspected aspiration pneumonia	Fever, tachycardia	Bowel obstruction	Cefotiam (4 days), SAM (15 days), intestinal resection	Alive, discharged (44 days)
11*	80s/F	Osteoporosis, dyslipidemia	Abdominal pain	Perforated appendicitis, peritonitis, intra-abdominal abscess	SAM (11 days), SAM and MTZ (8 days), appendectomy	Alive, discharged (19 days)
12	70s/M	Cerebral infarction history, cholecystectomy history	Chills, fever, vomiting	Bacteremia of unknown origin	CPFX and MTZ (3 days), CRO and MTZ (10 days)	Alive (outpatient)
13*	80s/M	Hypertension, cholecystectomy history, rectal cancer	Abdominal pain	Colorectal perforation	SAM (10 days), TZP (12 days), Hartmann's procedure	Alive, discharged (53 days)

402

403 AMP, ampicillin; CMZ, cefmetazole; CPFX, ciprofloxacin; transferred, transferred to another hospital.

404 *In cases marked with an asterisk, multiple pathogens were detected as follows: 2, *A. onderdonkii*, *Bacteroides uniformis*, *E. coli*, and

405 *Pseudomonas nitroreducens*; 5, *A. putredinis* and *E. coli*; 9, *A. putredinis* and *Flavonifractor plautii*; 10, *A. indistinctus* and

406 *K. pneumoniae*; 11, *A. onderdonkii* and *Bacteroides salyersiae*; and 13, *A. finegoldii* and *A. ihumii*.

407 †Most patients received multiple antibiotics; the two used for the longest duration are shown.

Bacteremia Caused by *Alistipes*

408 **Table 3.** Identification results of MALDI-TOF MS, 16S rRNA analysis and whole genome analysis for the strains isolated from patients
409 with *Alistipes* bacteremia

Case no.	Strain name	MALDI-TOF MS		16S rRNA analysis		Whole genome analysis	
		Proposed species	Score	Identified species	Similarity (%)	Identified species	ANI (%)
1	NA	<i>A. finegoldii</i>	2.0	NA	NA	NA	NA
2	NA	<i>A. onderdonkii</i>	2.1	NA	NA	NA	NA
3	NA	<i>A. finegoldii</i>	2.1	NA	NA	NA	NA
4	KML 24001	<i>A. onderdonkii</i>	2.3	<i>A. onderdonkii</i>	99.9	<i>A. onderdonkii</i>	98.3
5	KML 24002	<i>A. putredinis</i>	2.1	<i>A. putredinis</i>	100	<i>A. putredinis</i>	99.9
6	KML 24003	<i>A. finegoldii</i>	2.0	<i>A. finegoldii</i>	99.9	<i>A. finegoldii</i>	99.1
7	KML 24004	<i>A. indistinctus</i>	2.0	<i>A. indistinctus</i>	100	<i>A. indistinctus</i>	99.1
8	KML 24005	<i>A. onderdonkii</i>	2.1	<i>A. onderdonkii</i>	100	<i>A. onderdonkii</i>	99.6
9	KML 24006	<i>A. putredinis</i>	2.1	<i>A. putredinis</i>	100	<i>A. putredinis</i>	99.7
10	KML 24007	<i>A. indistinctus</i>	2.2	<i>A. indistinctus</i>	100	<i>A. indistinctus</i>	99.2
11	KML 24008	<i>A. onderdonkii</i>	2.0	<i>A. onderdonkii</i>	100	<i>A. onderdonkii</i>	98.8
12	KML 24009	<i>A. putredinis</i>	2.1	<i>A. putredinis</i>	99.9	<i>A. putredinis</i>	98.9
13	KML 24010	<i>A. finegoldii</i>	2.3	<i>A. finegoldii</i>	99.8	NA	NA
13	KML 24011	No identification	NA	<i>A. ihumii</i>	99.7	NA	NA

410

411 NA, not available.

412

413

Bacteremia Caused by *Alistipes*

414 **Table 4.** Minimum inhibitory concentration values ($\mu\text{g/mL}$) against antibiotics and antimicrobial-resistant genes of *Alistipes* strains

Strain name	PEN	SAM	AMC	TZP	CRO	FOX	IPM	CLI	MINO	MXF	MTZ	Resistant genes
Af, KML 24003	0.06	≤ 0.5	\leq 0.25	≤ 4	≤ 1	≤ 1	1	1	4 [*]	0.5	≤ 0.5	<i>adeF</i> , <i>tet(Q)</i>
Af, KML 24010	0.06	≤ 0.5	\leq 0.25	≤ 4	4	4	0.5	1	2	0.5	≤ 0.5	Not test
Ao, KML 24001	>1	1	0.5	≤ 4	8	4	1	\leq 0.12	4 [*]	> 4	≤ 0.5	<i>adeF</i> , <i>tet(Q)</i>
Ao, KML 24005	0.5	≤ 0.5	\leq 0.25	≤ 4	2	2	2	\leq 0.12	8 [*]	> 4	≤ 0.5	<i>adeF</i> , <i>tet(Q)</i>
Ao, KML 24008	> 1	2	1	≤ 4	> 32	8	1	0.5	8 [*]	> 4	≤ 0.5	<i>adeF</i> , <i>tet(Q)</i>
Ap, KML 24002	> 1	≤ 0.5	0.5	≤ 4	> 32	≤ 1	\leq 0.25	2 [*]	4 [*]	\leq 0.25	≤ 0.5	<i>adeF</i> , <i>tet(Q)</i> , <i>erm(G)</i>
Ap, KML 24006	> 1	1	2	≤ 4	> 32	4 [*]	1	\leq 0.12	8 [*]	1	≤ 0.5	<i>adeF</i> , <i>tet(Q)</i> , <i>cfxA4</i>
Ap, KML 24009	\leq 0.03	≤ 0.5	\leq 0.25	≤ 4	≤ 1	≤ 1	0.5	\leq 0.12	8 [*]	1	≤ 0.5	<i>adeF</i> , <i>tet(Q)</i>
Ain, KML 24004	> 1	8	8	≤ 4	> 32	32 [*]	1	\leq 0.12	\leq 0.25	1	≤ 0.5	<i>cfxA3</i>
Ain, KML 24007	> 1	2	1	≤ 4	32	32	1	\leq 0.12	\leq 0.25	1	≤ 0.5	Not detected
Total, MIC ₅₀	> 1	≤ 0.5	0.5	≤ 4	8	4	1	\leq 0.12	4	1	≤ 0.5	
Total, MIC ₉₀	> 1	2	2	≤ 4	> 32	32	1	1	8	> 4	≤ 0.5	

415

416 Af, *A. finegoldii*; Ao, *A. onderdonkii*; Ap, *A. putredinis*; Ain, *A. indistinctus*.

417

Bacteremia Caused by *Alistipes*

418 **Fig 1.** Small colonies of *Alistipes finegoldii* grown on agar medium in anaerobic culture for 48 h*

419

420 *Figure 1 shows *A. finegoldii* (arrow mark) and *Escherichia coli* ATCC 25922 colonies grown on

421 Brucella HK agar medium after 2 days of anaerobic culture.

422

